This article is more than 5 years old. Information may no longer be current.
PDT effective in minimally classic wet AMD at 6 months
Click Here to Manage Email Alerts
BULACH, Switzerland — Photodynamic therapy for minimally classic wet age-related macular degeneration seems to be effective at 6 months. This is the first prospective evidence that PDT is effective in minimally classic AMD, according to the makers of the PDT agent.
Vision outcomes at 6 months of Visudyne (verteporfin for injection, Novartis Ophthalmics) PDT for treatment of minimally classic wet age-related macular degeneration indicate the drug is well tolerated and effective, the drug’s developers announced.
The Visudyne in Minimally Classic (VIM) study includes 117 patients equally randomized to receive either placebo, Visudyne standard regimen or Visudyne reduced fluence (reduced light intensity). Novartis Ophthalmics, the drug’s co-developer and marketer, said outcomes at 6 months show the mean change in visual acuity scores of patients in both Visudyne treatment arms were statistically significantly better than the mean change in patients receiving placebo. The study will be continued through the 12-month mark.
According to a news release, additional details from the 6-month study results will be presented at the Macula Society meeting next February.